Hemophilia News Today Home | Hemophilia News Today
WEBSep 18, 2024 · Joint problems in hemophilia A are common despite prophylaxis. Almost two-thirds of men with moderate or severe hemophilia A have joint problems that cause …
Hemophilia News Today
Print media3 W Garden St Ste 700, Pensacola, FL 32502
Marstacimab recommended for EU approval for hemophilia A and B
WEB8 hours ago · A European Medicines Agency (EMA) committee has issued a positive opinion recommending the approval of marstacimab in the European Union for …
FDA OKs Factor VII Treatment for Hemophilia A and B …
WEBApr 2, 2020 · The U.S. Food and Drug Administration (FDA) approved Sevenfact (coagulation factor VIIa [recombinant]-jncw) for the treatment …
- Occupation: Managing Science Editor
- Estimated Reading Time: 3 mins
Top 10 Hemophilia Stories of 2021 - Hemophilia News Today
- — “Roctavian, Potential Hemophilia A Gene Therapy, Gets Fresh FDA Support” Our most …
- — “Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Phase 3 Data …
- — “Fitusiran Dosing in Trials Reduced to Lower Blood-clot Risk” Early in 2021, as reported …
- — “COVID-19 May Trigger Acquired Hemophilia A, Case Study Says” Researchers in the …
- — “Nasal Desmopressin Recall Affects Availability Through 2023” In February, Ferring …
Roctavian, Hem A Gene Therapy, Sustains Drop in …
WEBJan 13, 2021 · Roctavian’s use also reduced the need for replacement therapy by 99% — from 135.9 to two infusions per year. Across all 134 trial patients, a mean FVIII level of 42.9 international units per deciliter …
No real COVID-19 infection impact seen for hemophilia patients
WEB4 days ago · Investigating the ‘specific impact’ of COVID-19 infection on hemophilia patients. Hemophilia is mainly caused by mutations in the genes that provide …
Our Top 10 Most-read Hemophilia Stories and Features of 2020
WEBJan 4, 2021 · No. 1 – “ Valrox, Potential Hemophilia A Gene Therapy, May Cost Up to $3 Million, BioMarin Says ”. Our most-read story of 2020 covered the news that, if …
Most Hemophilia Patients Bleed-free 3 Years After Roctavian Trial
WEBJan 13, 2023 · Prior findings from the trial showed that more than 80% of participants were bleed-free after two years. Most participants also were off standard replacement …
Potential Hemophilia B Therapy AMT-061 Improves FIX …
WEBJan 10, 2020 · The safety and effectiveness of AMT-061 are currently being investigated in three patients with severe hemophilia B (those whose FIX activity is 1% or less) participating in an open-label, single-dose Phase …
Over 50% of hemophilia patients not ‘fine’ but hide symptoms: …
WEBOct 13, 2023 · Over 2,500 patients, caregivers, hematologists surveyed. Globally, more than 1 million people are estimated to have hemophilia, a rare bleeding disorder caused …